The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …

In this Timeline, we describe the characteristics of tumour antigens that are recognized by
spontaneous T cell responses in cancer patients and the paths that led to their identification …

Despite impressive clinical success, cancer immunotherapy based on immune checkpoint
blockade remains ineffective in many patients due to tumoral resistance. Here we use the …

With the recent developments of adoptive T cell therapies and the use of new monoclonal
antibodies against the immune checkpoints, immunotherapy is at a turning point. Key …

Epigenetic silencing of immune-related genes is a striking feature of the cancer genome that
occurs in the process of tumorigenesis. This phenomena impacts antigen processing and …

Identifying T-cell receptors (TCRs) that bind tumor-associated antigens (TAAs) with optimal
affinity is a key bottleneck in the development of adoptive T-cell therapy of cancer. TAAs are …

The proteasome is responsible for the breakdown of cellular proteins. Proteins targeted for
degradation are allowed inside the proteasome particle, where they are cleaved into small …

Cancer is a complex disease that can originate in virtually all the tissues of the body, and
tumors progress through many different stages during their development. While genetic …

Mouse models of cancer immunology provide excellent systems in which to study and test
biological mechanisms of the immune response against cancer. Historically, these models …

Therapeutic vaccination regimens inducing clinically effective tumor-specific CD8+ T
lymphocyte (CTL) responses are an unmet medical need. We engineer two distantly related …